Fujian Haixi Pharma Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
200
- Stock Symbol
-
02637
- Investments
-
1
- Share Price
-
$19.89
- (As of Friday Closing)
Fujian Haixi Pharma General Information
Description
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
Contact Information
Website
www.hxpharma.comCorporate Office
- 3rd and 4th Floor, Block B, No. 177, Jinda Road
- Jianxin Town, Cangshan District
- Fuzhou, Fujian 350028
- China
Corporate Office
- 3rd and 4th Floor, Block B, No. 177, Jinda Road
- Jianxin Town, Cangshan District
- Fuzhou, Fujian 350028
- China
Fujian Haixi Pharma Stock Performance
As of 13-Nov-2026, Fujian Haixi Pharma’s stock price is $19.89. Its current market cap is $1.57B with 78.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $19.89 | $19.95 | $15.93 - $38.59 | $1.57B | 78.7M | 96.8K | $0.36 |
Fujian Haixi Pharma Financials Summary
As of 30-Jun-2026, Fujian Haixi Pharma has a trailing 12-month revenue of $84.9M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,633,755 | 1,338,074 | ||
| Revenue | 84,875 | 80,981 | 65,039 | 44,755 |
| EBITDA | 27,769 | 21,643 | 19,385 | |
| Net Income | 24,839 | 24,617 | 18,964 | 16,602 |
| Total Assets | 289,403 | 263,939 | 103,535 | 79,218 |
| Total Debt | 11,892 | 15,743 | 7,792 | 7,066 |
Fujian Haixi Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Fujian Haixi Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Fujian Haixi Pharma Patents
Fujian Haixi Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026223723-A1 | A compound for use in the treatment of cancer | Pending | 22-Apr-2025 | ||
| WO-2026223663-A1 | Crystal form of the compound, preparation method and uses thereof | Pending | 22-Apr-2025 | ||
| WO-2026223721-A1 | Methods of treating cancer | Pending | 22-Apr-2025 | ||
| US-20260116871-A1 | Tyrosine kinase inhibitors and uses thereof | Pending | 24-Oct-2024 | ||
| WO-2026086911-A1 | Tyrosine kinase inhibitors and uses thereof | Pending | 24-Oct-2024 | C07D409/04 |
Fujian Haixi Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Fujian Haixi Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Fujian Haixi Pharma Investments (1)
Fujian Haixi Pharma’s most recent deal was a Later Stage VC with NeuExcell Therapeutics for . The deal was made on 04-May-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NeuExcell Therapeutics | 04-May-2023 | Later Stage VC | Drug Discovery |
Fujian Haixi Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Fujian Haixi Pharma FAQs
-
When was Fujian Haixi Pharma founded?
Fujian Haixi Pharma was founded in 2012.
-
Where is Fujian Haixi Pharma headquartered?
Fujian Haixi Pharma is headquartered in Fuzhou, China.
-
What is the size of Fujian Haixi Pharma?
Fujian Haixi Pharma has 200 total employees.
-
What industry is Fujian Haixi Pharma in?
Fujian Haixi Pharma’s primary industry is Drug Discovery.
-
Is Fujian Haixi Pharma a private or public company?
Fujian Haixi Pharma is a Public company.
-
What is Fujian Haixi Pharma’s stock symbol?
The ticker symbol for Fujian Haixi Pharma is 02637.
-
What is the current stock price of Fujian Haixi Pharma?
As of 13-Nov-2026 the stock price of Fujian Haixi Pharma is $19.89.
-
What is the current market cap of Fujian Haixi Pharma?
The current market capitalization of Fujian Haixi Pharma is $1.57B.
-
What is Fujian Haixi Pharma’s current revenue?
The trailing twelve month revenue for Fujian Haixi Pharma is $84.9M.
-
What is Fujian Haixi Pharma’s annual earnings per share (EPS)?
Fujian Haixi Pharma’s EPS for 12 months was $0.36.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
